AmpliPhi raises $7m in placement
Bacteriophage-based treatment company AmpliPhi Biosciences has completed a $7 million private placement to fund its development activities.
The financing round was led by established life sciences investors RA Capital Management and Third Security. BioScience Managers also participated.
“We are very pleased to have the support of these outstanding life science investors,” AmpliPhi CEO Philip J Young said.
As part of its investment, Third Security will appoint managing director Julian P Kirk to the AmpliPhi board. Existing AmpliPhi board members Dr Caroline Williams and Tony Gellert have meanwhile stepped down.
US-based AmpliPhi last year merged with Australia’s Special Phage Services. Gellert had joined the board as a result of this merger.
The combined company is focused on developing antibacterial treatments for antibiotic-resistant bacterial infections. Its lead program centres on treatments for chronic and acute lung infections.
No clear link between paracetamol in pregnancy and autism/ADHD
Existing evidence does not clearly link paracetamol (acetaminophen) use during pregnancy with...
Light at night can increase heart disease risk
Being exposed to bright light at night can significantly increase your chances of developing...
Scientists find new driver of ovarian cancer spread
A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...
